Chemotherapy and Peripheral Stem Cell Transplant With or Without Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

DISEASE CHARACTERISTICS:

* Histologically confirmed relapsed B-cell non-Hodgkin's lymphoma (NHL)

  * Diffuse large cell B-cell lymphoma
  * Grade III follicular center-cell lymphoma
  * Primary mediastinal B-cell lymphoma
* CD20 positive
* First relapse after doxorubicin containing regimen
* Documented remission of at least 3 months after first-line chemotherapy
* No Epstein-Barr virus post-transplantation lymphoproliferative disorder
* No CNS involvement

PATIENT CHARACTERISTICS:

Age:

* 18 to 65

Performance status:

* WHO 0-1

Life expectancy:

* Not specified

Hematopoietic:

* Not specified

Hepatic:

* No hepatic dysfunction
* Bilirubin less than 2.5 times upper limit of normal (ULN)
* Transaminases less than 2.5 times ULN

Renal:

* No renal dysfunction
* Creatinine less than 2.0 mg/dL OR
* Creatinine clearance greater than 40 mL/min

Cardiovascular:

* No severe cardiac dysfunction
* No New York Heart association class II-IV heart disease

Pulmonary:

* No severe pulmonary dysfunction
* Vital capacity or diffusion capacity at least 70% predicted unless related to NHL involvement

Other:

* No active uncontrolled infection
* HIV negative
* No intolerance to exogenous protein administration

PRIOR CONCURRENT THERAPY:

Biologic therapy:

* At least 1 month since prior immunotherapy

Chemotherapy:

* See Disease Characteristics
* At least 1 month since prior chemotherapy

Endocrine therapy:

* Not specified

Radiotherapy:

* At least 1 month since prior radiotherapy

Surgery:

* Not specified